Hinova Pharmaceuticals Inc. A (688302) - Total Assets
Based on the latest financial reports, Hinova Pharmaceuticals Inc. A (688302) holds total assets worth CN¥1.39 Billion CNY (≈ $203.78 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hinova Pharmaceuticals Inc. A - Total Assets Trend (2019–2024)
This chart illustrates how Hinova Pharmaceuticals Inc. A's total assets have evolved over time, based on quarterly financial data. Also see Hinova Pharmaceuticals Inc. A market capitalisation for the company's overall valuation and market capitalisation.
Hinova Pharmaceuticals Inc. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Hinova Pharmaceuticals Inc. A's total assets of CN¥1.39 Billion consist of 65.0% current assets and 35.0% non-current assets. Review 688302 current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 46.5% |
| Accounts Receivable | CN¥0.00 | 0.0% |
| Inventory | CN¥4.56K | 0.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥30.56 Million | 2.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Hinova Pharmaceuticals Inc. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Hinova Pharmaceuticals Inc. A stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hinova Pharmaceuticals Inc. A's current assets represent 65.0% of total assets in 2024, a decrease from 89.2% in 2019.
- Cash Position: Cash and equivalents constituted 46.5% of total assets in 2024, up from 44.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 2.2% of total assets.
Hinova Pharmaceuticals Inc. A Competitors by Total Assets
Key competitors of Hinova Pharmaceuticals Inc. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥729.16 Million |
|
Pulike Biological Engineering
SHG:603566
|
China | CN¥3.09 Billion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $423.10 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
Hinova Pharmaceuticals Inc. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.55 | 7.21 | 4.72 |
| Quick Ratio | 7.54 | 7.21 | 4.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥879.45 Million | CN¥881.13 Million | CN¥683.82 Million |
Hinova Pharmaceuticals Inc. A - Advanced Valuation Insights
This section examines the relationship between Hinova Pharmaceuticals Inc. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.65 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -8.7% |
| Total Assets | CN¥1.36 Billion |
| Market Capitalization | $486.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hinova Pharmaceuticals Inc. A's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hinova Pharmaceuticals Inc. A's assets decreased by 8.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hinova Pharmaceuticals Inc. A (2019–2024)
The table below shows the annual total assets of Hinova Pharmaceuticals Inc. A from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.36 Billion ≈ $199.24 Million |
-8.71% |
| 2023-12-31 | CN¥1.49 Billion ≈ $218.26 Million |
-14.03% |
| 2022-12-31 | CN¥1.74 Billion ≈ $253.90 Million |
+76.62% |
| 2021-12-31 | CN¥982.35 Million ≈ $143.75 Million |
-17.34% |
| 2020-12-31 | CN¥1.19 Billion ≈ $173.91 Million |
+2557.85% |
| 2019-12-31 | CN¥44.72 Million ≈ $6.54 Million |
-- |
About Hinova Pharmaceuticals Inc. A
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501… Read more